Bayh-Dole Act — Patent Rights from Federally Funded Research

The Bayh-Dole Act (35 U.S.C. §§ 200–212) allows universities, small businesses, and nonprofit organizations to retain ownership of inventions made with federal research funding — and to patent and license those inventions for commercial use. Before Bayh-Dole (1980), the federal government owned the patents on roughly 28,000 inventions resulting from billions of dollars in taxpayer-funded research — and fewer than 5% had been licensed to industry. Groundbreaking discoveries sat on government shelves because federal agencies had no mechanism or incentive to commercialize them. Bayh-Dole changed the incentives: by letting research institutions own and profit from their inventions (subject to certain conditions protecting the public interest), it created the modern university technology transfer industry. Today, university patent licensing generates over $4 billion annually in license income, has spawned thousands of startup companies, and has brought taxpayer-funded innovations from the laboratory to the marketplace — including foundational technologies in biotechnology, software, medical devices, and clean energy.

Current Law (2026)

Legal Authority

• 35 U.S.C. § 200 — Policy and objective (U.S. policy to use the patent system to promote utilization of inventions arising from federally funded research; to promote collaboration between commercial concerns and nonprofit organizations; to ensure the government obtains sufficient rights)
• 35 U.S.C. § 202 — Disposition of rights (contractors (universities, small businesses, nonprofits) may elect to retain title to subject inventions; must disclose inventions promptly; must file patent applications; government retains a royalty-free license for government purposes)
• 35 U.S.C. § 203 — March-in rights (funding agency may require the contractor to grant licenses if the invention is not being practically applied, to meet health or safety needs, or to satisfy U.S. manufacturing requirements)
• 35 U.S.C. § 204 — Preference for United States industry (any products embodying a subject invention or produced through use of a subject invention must be manufactured substantially in the United States, unless a waiver is granted)
• 35 U.S.C. § 207 — Domestic and foreign protection of federally owned inventions (government agencies may apply for patents on inventions they own and license them)
• 35 U.S.C. § 209 — Licensing federally owned inventions (agencies may grant exclusive or partially exclusive licenses for federally owned inventions under specified conditions)

How It Works

The Bayh-Dole Act of 1980 (35 U.S.C. § 200 et seq.) struck a fundamental bargain: when a university, small business, or nonprofit makes an invention while performing federally-funded research, the institution may elect to retain title to the patent rather than assigning it to the government. In exchange, the institution must disclose the invention to the funding agency within 2 months, elect title within 2 years, file a patent application, grant the government a non-exclusive royalty-free license for government purposes, and share licensing revenues with the inventor. Revenue-sharing formulas vary by institution but typically give inventors 15–50% of net licensing income; some Bayh-Dole inventions have generated hundreds of millions — Stanford's early Google search algorithm patents, Columbia's Axel biotechnology patents, and the University of Wisconsin's vitamin D research.

The government retains a backstop through march-in rights: if a Bayh-Dole invention is not being "practically applied" for the public's benefit on reasonable terms, the funding agency can compel the patent holder to license the technology to other parties. March-in can also be invoked for health or safety needs or failure to substantially manufacture in the United States (§ 204, waivable if domestic manufacturing is not commercially feasible). Despite periodic petitions — including high-profile pharmaceutical pricing campaigns arguing NIH-funded drugs should face march-in when priced unaffordably — the government has never exercised march-in rights in the Act's 45-year history. Bayh-Dole created the modern university technology transfer office: nearly every research university now has one managing invention disclosures, patent applications, and licenses. U.S. universities collectively file approximately 20,000 patent applications per year, execute over 9,000 licenses, and launch roughly 1,000 startup companies annually from federally-funded research.

How It Affects You

If you're a university researcher using federal grant funding: Any invention you make using federal money — from NIH grants, NSF awards, DOE contracts, or any other federal funding source — is governed by Bayh-Dole. The most important thing to do is disclose promptly to your technology transfer office (TTO). Most universities require disclosure within 60 days of invention conception; missing this window can jeopardize patent rights and forfeit your share of licensing revenue. Your institution files the patent (paying costs), then licenses the technology and splits royalties with you as the inventor — royalty-sharing policies vary by university but typically give inventors 25–40% of net licensing revenue after patent costs. Your institution must also disclose the federally funded invention to the funding agency, elect to pursue patent rights, and file a patent application within 1 year of election. If your TTO decides not to pursue rights, you can request a waiver to file yourself. The federal government retains a government-use license (it can use the invention for free forever) and march-in rights — the right to require licensing if the invention is not being developed for public benefit — though march-in rights have never been successfully exercised to force licensing against an inventor's wishes.

If you're an entrepreneur or startup founder looking to license university technology: University technology transfer offices are actively looking for commercialization partners — the TTO's job is to get inventions out of the lab and into the market, and licensing to startups is a primary pathway. Start by searching university patent databases: MIT's TLO at tlo.mit.edu, Stanford's OTL at otl.stanford.edu, and most major research universities publish searchable patent portfolios. For biomedical technologies, the NIH National Cancer Institute also directly licenses federally owned inventions at techtransfer.cancer.gov. License negotiations typically involve an upfront fee ($10K–$100K+), milestone payments, and a running royalty (1–5% of net sales is common for early-stage tech). Many TTOs prefer working with startups and may offer favorable terms in exchange for equity. Expect 3–9 months for license negotiation. Key question to ask: is the patent issued or just filed? An issued patent provides clearer protection than a pending application.

If you're a pharmaceutical or biotech company: NIH-funded research underlies many of the most commercially significant drugs — including foundational patents on mRNA technology, cancer therapies, and antibody platforms that have generated billions in revenue. The march-in rights provision (35 U.S.C. § 203) has been the subject of renewed policy attention: in 2023, the Biden administration proposed guidance that would allow federal agencies to march in and require licensing when a product's price is "unreasonable" — a significant expansion that was controversial because it threatened to undermine the investment incentives Bayh-Dole was designed to create. The Trump administration has not continued that guidance. For companies building products on Bayh-Dole-licensed university patents, the march-in risk is low by historical precedent but worth monitoring for federally funded inventions where pricing becomes politically salient. Use the NIH iEdison database (iedison.gov) to research federal funding underlying specific university patents.

If you're a patient or taxpayer concerned about drug prices: The Bayh-Dole debate ultimately turns on a simple question: does allowing private companies to profit from publicly funded inventions accelerate innovation (the Bayh-Dole argument) or enable price gouging on drugs taxpayers paid to develop (the critic's argument)? The pharmaceutical industry credits Bayh-Dole with catalyzing the U.S. biotech industry — 100+ drugs and vaccines currently in use trace back to NIH-funded research. Critics point to drugs like Xtandi (prostate cancer, developed on NIH-funded patents, with a list price of approximately $189,900/year in the U.S. as of 2024) as evidence that the public does not adequately capture the value of its investment. The unresolved policy question — how to use march-in rights or upstream contract conditions to address pricing — will continue to be debated in Congress and at the NIH.

State Variations

Bayh-Dole is exclusively federal law:

• State universities are subject to Bayh-Dole when they receive federal research funding
• Some states have additional technology transfer policies or incentive programs
• State tax treatment of patent licensing income varies
• State economic development agencies may partner with university TTOs to promote local commercialization

Implementing Regulations

• 37 CFR Part 401 — Rights to Inventions Made by Nonprofit Organizations and Small Business Firms: the NIST/DOC implementing regulation for the Bayh-Dole Act, establishing the standard patent rights clause that must be included in every federal funding agreement with a nonprofit institution or small business firm:

  • Disclosure obligation: grantees must disclose each subject invention (any invention conceived or first actually reduced to practice under the funding agreement) to the federal agency within two months of the inventor first disclosing it in writing within the organization; the two-month window starts from internal disclosure, not from the invention date
  • Election of title: the nonprofit or small business may elect to retain title to a subject invention by notifying the federal agency within two years of disclosure; this is the core Bayh-Dole right — universities and small firms own inventions that, before 1980, would have defaulted to the federal government; failure to elect within two years allows the agency to take title
  • Patent filing obligation: if a contractor elects title, it must file a U.S. patent application within one year and prior to any statutory bar; the government retains a royalty-free, nonexclusive license to practice the invention for government purposes — this is the government's perpetual backstop right that exists regardless of whether the patent is ever licensed commercially
  • March-in rights (§ 401.6): federal agencies may "march in" and require the patent holder to grant additional licenses if the grantee fails to achieve practical application within a reasonable time, fails to satisfy public health or safety needs, or fails to meet requirements for U.S. preference in manufacturing; march-in has never been successfully exercised in the Act's 45-year history — NIH has repeatedly declined to exercise march-in for pharmaceutical patents despite petitions arguing that high drug prices warrant it (most recently denying an Xtandi march-in petition in February 2024); the Biden administration's December 2023 draft framework indicated more willingness to consider price as a factor in march-in analysis, but the framework was never finalized <!-- FACTCHECK 2026-05-11: claim that Trump administration formally rescinded the Biden draft march-in framework in 2025 could not be confirmed in independent sources; hedged. — wiki-factcheck -->
  • U.S. manufacturing preference: products using a Bayh-Dole invention must be substantially manufactured in the U.S. unless the grantee can demonstrate no U.S. manufacturer is willing to license on reasonable terms; waivers are available and are commonly granted for international products

• 2 CFR 200.315 — OMB Uniform Guidance — intangible property (intellectual property provisions for federally funded research, including inventions, patents, and copyrights arising under federal awards)

• 37 CFR Part 404 — Licensing of Government-Owned Inventions: the implementing regulation for 35 U.S.C. § 207-209, governing how federal agencies license patents they own outright (distinct from Bayh-Dole, which governs contractor/university rights). When a federal agency conducts its own research (NIH intramural labs, NASA, DOE national labs, NIST, USDA research centers), the resulting inventions belong to the government — and Part 404 is the framework for licensing those government-owned patents to private parties:

  • § 404.4 — Authority: all federally owned inventions must be made available for licensing "as deemed appropriate in the public interest"; agencies must notify the public of available inventions (through announcement in the Official Gazette and other publications); the licensing authority is consistent with Bayh-Dole's framework — the same commercialization goal applies, but the licensor is a federal agency rather than a university
  • § 404.6 — Nonexclusive licenses: may be granted without public notice; any person who submits a satisfactory commercialization plan and agrees to the standard license terms can receive a nonexclusive license to practice a government-owned invention; nonexclusive licenses are administratively simpler and carry no obligation to develop the technology
  • § 404.7 — Exclusive licenses: exclusive, co-exclusive, or partially exclusive licenses on government-owned inventions can be granted only after (1) publication of notice in the Official Gazette (giving 60 days for competing applications), (2) a determination that exclusive licensing is necessary to achieve practical application of the invention, (3) a finding that the proposed licensee has adequate resources to develop the invention, and (4) a determination that the license is in the public interest; exclusive licenses may be limited in scope (to a field of use, territory, or period) even if initially exclusive; the high threshold for exclusive licensing reflects the public ownership interest in government-funded inventions
  • § 404.5 — Standard conditions on all licenses: every license issued under Part 404 must include: a U.S. manufacturing preference (products using the invention must be substantially manufactured in the U.S. unless waived); a government-use reservation (the government retains a royalty-free license to use the invention for government purposes regardless of any commercial license); a progress reporting obligation (licensees must report development efforts); and termination rights if the licensee fails to bring the invention to practical application within a specified period
  • § 404.10 — Modification and termination: licenses may be terminated or modified after notice and opportunity for the licensee to respond; grounds include failure to comply with license terms, failure to achieve practical application within the timeline, or public health/safety needs requiring broader access; the termination power is the analog to Bayh-Dole's march-in rights — government retains leverage even after granting an exclusive license

• 10 CFR Part 784 — DOE Patent Waiver Regulation: governs when DOE waives its special statutory right — under 42 U.S.C. § 2182 (AEA § 152) — to claim title to inventions made under DOE contracts that relate to nuclear weapons, nuclear material production, and special nuclear material. The AEA § 2182 right operates independently of and in addition to Bayh-Dole. Under § 2182, any invention conceived or first reduced to practice in a DOE-funded program that is "useful in the production or utilization of special nuclear material or atomic energy" belongs to the government — automatically, without any election required — unless DOE waives that right.

  • § 784.3 — Policy: DOE's default for AEA-covered inventions is government ownership; this is the opposite of Bayh-Dole's default for other federal funding. The rationale: nuclear-related inventions raise national security concerns that justify tighter government control than ordinary research. Bayh-Dole did not displace AEA § 2182 — both apply simultaneously, and AEA § 2182 governs when it conflicts with Bayh-Dole for nuclear inventions
  • § 784.4 — Advance waiver: DOE may grant an advance waiver — waiving its § 2182 rights before a contract begins — for all inventions that may arise under a specific contract; advance waivers are appropriate when DOE determines that contractor ownership will best promote development and commercialization; a waiver application must describe the work, the likely inventions, and the contractor's commercialization plan
  • § 784.11 — Bases for granting waivers: DOE grants a waiver when the contractor demonstrates that (a) commercial development is likely to promote widespread use of the invention, (b) government ownership is not needed for national security, (c) the contractor has a viable development and commercialization plan, and (d) the contractor agrees to license the invention broadly; waiver is typically not granted for inventions directly related to nuclear weapons design or special nuclear material production processes — those remain government-owned for security reasons
  • § 784.12 — Waiver terms and conditions: all waivers come with conditions parallel to Bayh-Dole requirements: inventor disclosure obligations, government-use license reservation, U.S. manufacturing preference, march-in rights, and patent filing obligations; a waived contractor is in effectively the same position as a Bayh-Dole contractor for the waived invention
  • § 784.10 — Public record: DOE maintains a publicly available record of all waiver determinations — what was waived, to whom, and on what terms

  The practical effect: most DOE national laboratory inventions in energy technology, materials science, computation, and basic research are covered by advance waivers and treated like Bayh-Dole inventions, with the laboratory's tech transfer office handling licensing. Inventions in weapons design, special nuclear material processing, and nuclear security remain government-owned. The AEA § 2182 / Part 784 framework is why DOE maintains a separate patent portfolio structure from other agencies — NNSA and the weapons laboratories use a more restrictive waiver framework, while non-weapons DOE programs (Office of Science, EERE, ARPA-E) use advance waivers to align with the Bayh-Dole commercialization incentive structure.

  Part 404 governs a significant portfolio: NIH's intramural research program (the largest biomedical research program in the world) produces hundreds of patents annually that are available for licensing through NIH's Office of Technology Transfer at techtransfer.nih.gov; NASA patents cover aerospace propulsion, materials, sensors, and software; NIST patents cover measurement, materials, and standards; USDA patents cover agricultural biotechnology; NOAA patents cover weather instruments and satellite technology. Unlike university Bayh-Dole licenses, government-owned invention licenses are directly negotiated with federal technology transfer offices — no intermediate university TTO. The licensing terms and database of available inventions are searchable at patents.google.com (filtering for U.S. government as assignee) and at individual agency tech transfer websites.

Pending Legislation

No standalone Bayh-Dole reform bills have been introduced in the 119th Congress. March-in rights and federally funded research patent policy discussions appear in broader innovation and research legislation — see Patent Law and Federal Research & Development.

Recent Developments

The debate over march-in rights for pharmaceutical pricing has intensified. In 2023, NIH issued a draft framework proposing that the price of a product developed with federal funding could be considered when evaluating whether the invention is being made available on "reasonable terms" — potentially enabling march-in based on drug pricing. Pharmaceutical industry groups argue this would undermine Bayh-Dole's incentive structure. The Biden administration's executive actions on competition and drug pricing referenced Bayh-Dole authorities. Separately, the Act's application to AI-generated inventions and the growing role of international collaboration in federally funded research present new interpretive challenges. See NIST for the AI standards framework that intersects with federally funded AI research. University technology transfer continues to grow — total license income, startup formation, and patent filings have all increased over the past decade.

• Biden draft march-in framework remains unfinalized: The Biden NIH's December 2023 draft framework proposed that price could be a factor in determining whether a Bayh-Dole-funded invention is being made available on "reasonable terms" — a potential expansion of the basis for march-in rights. The framework was never finalized before the change in administration. The Trump administration's January 2025 executive order reversing Biden drug-pricing initiatives did not directly address Bayh-Dole march-in policy in its public text. Pharmaceutical industry groups oppose using march-in as a pricing tool; advocates for drug pricing reform support it. As of May 2026, no administration in the Act's history has successfully exercised march-in rights based on price.
• AI-generated inventions and Bayh-Dole: The emergence of AI systems that can generate patentable inventions — or contribute substantially to inventive processes in federally funded research — has created unsettled Bayh-Dole questions. If AI (not a human inventor) generates an invention in the course of federally funded research, do the university's Bayh-Dole rights attach? USPTO's position is that AI cannot be a legal inventor; the invention would need a human inventor with Bayh-Dole rights. How universities disclose AI's role in federally funded inventions, and whether that disclosure is required, is an area of active policy development.
• Research security and Bayh-Dole compliance: The FBI and NSF's research security enforcement (related to the China Initiative and successor programs) has intersected with Bayh-Dole. Foreign talent programs — where researchers disclosed affiliations with foreign government-sponsored research programs — raised questions about whether foreign entities could acquire Bayh-Dole rights through university collaborations. NSF, NIH, and DOD have tightened disclosure requirements for foreign financial interests as part of research security reform, affecting the structure of international research collaborations funded by federal grants.
• University tech transfer income records: FY2023 AUTM data showed U.S. universities generating over $4 billion in licensing income, forming 1,500+ new startup companies from federally funded research, and executing 15,000+ new licenses. The compounding effect of Bayh-Dole — now 44 years in — is visible in clusters of university-affiliated industry around major research universities. The NIH's own portfolio has produced dozens of blockbuster drugs and vaccines, including mRNA COVID vaccine technology initially developed with federal funding.